Teva Aims To Revoke IP For BMS Blockbuster Blood Thinner
Teva Pharmaceuticals is suing a subsidiary of Bristol Myers Squibb to invalidate the European patent for the American pharmaceutical company's blockbuster blood thinner Eliquis, saying the patent's description reveals no inventive...To view the full article, register now.
Already a subscriber? Click here to view full article